查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008986

溶瘤病毒療法市場報告：按病毒類型、應用、最終用途和地區分類（2026-2034 年）

Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球溶瘤病毒療法市場規模達2.22億美元。展望未來，IMARC Group預測，到2034年，市場規模將達到8.154億美元，2026年至2034年的複合年成長率為15.09%。

溶瘤病毒療法是一種利用病毒感染並摧毀癌細胞的免疫療法。目前使用的病毒種類繁多，包括天然病毒和基因改造病毒，例如單純皰疹病毒、新城疫病毒、牛痘病毒、腺病毒、呼腸孤病毒和微小核糖核酸病毒。溶瘤病毒療法透過活化危險訊號來觸發免疫反應，廣泛用於治療固態腫瘤、惡性黑色素瘤和無法切除的病灶。它利用病毒僅感染並摧毀靶向癌細胞，從而達到根除腫瘤的目的。與化療相比，溶瘤病毒療法毒性小、療效高，並能延長癌症患者的存活期。因此，它在醫院、診所和癌症研究機構中得到廣泛應用。

溶瘤病毒療法市場的發展趨勢：

全球癌症發生率的上升為該市場帶來了光明的前景。溶瘤病毒療法因其強大的抗腫瘤特性以及能夠精準靶向腫瘤而不損傷周圍組織的能力，被廣泛用於治療多種癌症，包括膠質乳癌瘤、乳腺癌、肺癌和前列腺癌。因此，該療法在治療各種惡性腫瘤（例如骨髓惡性腫瘤、淋巴瘤、白血病和多發性骨髓瘤）的廣泛應用，正在推動市場成長。此外，患者對各種癌症治療（包括手術、放射線治療、化療和免疫療法）不良健康影響的日益關注，也顯著促進了市場成長。另外，針對溶瘤病毒（例如皰疹病毒、腺病毒和痘苗病毒）的臨床研究已進入最後階段，並顯示出令人鼓舞的實驗結果，這將進一步推動市場成長。預計推動市場成長的其他因素包括對先進治療方法和新型療法的需求不斷成長，以及政府加強提高公眾對各種癌症病因的認知並促進早期診斷。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：溶瘤病毒療法的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依病毒類型分類

  • 基因改造溶瘤病毒
    • 主要部分
      • 單純皰疹病毒
      • 腺病毒
      • 牛痘病毒
  • 溶瘤野生型病毒
    • 主要部分
      • 呼腸孤病毒
      • 新城疫病毒
      • 水痘炎病毒

第7章 市場區隔：依應用領域分類

  • 固體癌
    • 主要部分
      • 乳癌
      • 攝護腺癌
      • 肺癌
      • 膠質母細胞瘤
  • 黑色素瘤
    • 主要部分
      • 骨髓惡性腫瘤
      • 淋巴瘤
      • 白血病
      • 多發性骨髓瘤

第8章 市場區隔：依最終用途分類

  • 醫院
  • 專科診所
  • 癌症研究機構

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Amgen Inc.
    • Dnatrix Inc.
    • Genelux Corporation
    • Lokon Pharma AB
    • Replimune Group Inc.
    • Rigvir Ltd.
    • Sorrento Therapeutics
    • Takara Bio Inc.（Takara Holdings Inc.）
    • Targovax
    • TILT Biotherapeutics Ltd
    • Transgene SA
    • Vyriad
Product Code: SR112026A6592

The global oncolytic virus therapies market size reached USD 222.0 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 815.4 Million by 2034, exhibiting a growth rate (CAGR) of 15.09% during 2026-2034.

Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.

ONCOLYTIC VIRUS THERAPIES MARKET TRENDS:

The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy , chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.

KEY MARKET SEGMENTATION:

Breakup by Virus Type:

  • Genetically Engineered Oncolytic Viruses
    • Herpes Simplex Virus
    • Adenovirus
    • Vaccinia Virus
  • Oncolytic Wild-Type Viruses
    • Reovirus
    • Newcastle Disease Virus
    • Vesicular Stomatitis Virus

Breakup by Application:

  • Solid Tumors
    • Breast Cancer
    • Prostate Cancer
    • Lung Cancer
    • Glioblastoma
  • Melanoma
    • Hematological Malignancies
    • Lymphoma
    • Leukemia
    • Myeloma

Breakup by End Use:

  • Hospitals
  • Specialty Clinics
  • Cancer Research Institute

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global oncolytic virus therapies market in 2025?

2. What is the expected growth rate of the global oncolytic virus therapies market during 2026-2034?

3. What are the key factors driving the global oncolytic virus therapies market?

4. What has been the impact of COVID-19 on the global oncolytic virus therapies market?

5. What are the key regions in the global oncolytic virus therapies market?

6. Who are the key players/companies in the global oncolytic virus therapies market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncolytic Virus Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Virus Type

  • 6.1 Genetically Engineered Oncolytic Viruses
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Herpes Simplex Virus
      • 6.1.2.2 Adenovirus
      • 6.1.2.3 Vaccinia Virus
    • 6.1.3 Market Forecast
  • 6.2 Oncolytic Wild-Type Viruses
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Reovirus
      • 6.2.2.2 Newcastle Disease Virus
      • 6.2.2.3 Vesicular Stomatitis Virus
    • 6.2.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Solid Tumors
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Breast Cancer
      • 7.1.2.2 Prostate Cancer
      • 7.1.2.3 Lung Cancer
      • 7.1.2.4 Glioblastoma
    • 7.1.3 Market Forecast
  • 7.2 Melanoma
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Hematological Malignancies
      • 7.2.2.2 Lymphoma
      • 7.2.2.3 Leukemia
      • 7.2.2.4 Myeloma
    • 7.2.3 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cancer Research Institute
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Dnatrix Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Genelux Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Lokon Pharma AB
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Replimune Group Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Rigvir Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Sorrento Therapeutics
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Takara Bio Inc. (Takara Holdings Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Targovax
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 TILT Biotherapeutics Ltd
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Transgene SA
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Vyriad
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Oncolytic Virus Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Oncolytic Virus Therapies Market: Breakup by Virus Type (in %), 2025
  • Figure 5: Global: Oncolytic Virus Therapies Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Oncolytic Virus Therapies Market: Breakup by End Use (in %), 2025
  • Figure 7: Global: Oncolytic Virus Therapies Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Oncolytic Virus Therapies (Genetically Engineered Oncolytic Viruses) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Oncolytic Virus Therapies (Genetically Engineered Oncolytic Viruses) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Oncolytic Virus Therapies (Oncolytic Wild-Type Viruses) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Oncolytic Virus Therapies (Oncolytic Wild-Type Viruses) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Oncolytic Virus Therapies (Solid Tumors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Oncolytic Virus Therapies (Solid Tumors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Oncolytic Virus Therapies (Melanoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Oncolytic Virus Therapies (Melanoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Oncolytic Virus Therapies (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Oncolytic Virus Therapies (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Oncolytic Virus Therapies (Specialty Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Oncolytic Virus Therapies (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Oncolytic Virus Therapies (Cancer Research Institute) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Oncolytic Virus Therapies (Cancer Research Institute) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: North America: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: North America: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: United States: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: United States: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Canada: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Canada: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Asia-Pacific: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Asia-Pacific: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: China: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: China: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Japan: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Japan: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: India: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: India: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: South Korea: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: South Korea: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Australia: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Australia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Indonesia: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Indonesia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Others: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Europe: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Europe: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Germany: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Germany: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: France: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: France: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: United Kingdom: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: United Kingdom: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Italy: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Italy: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Spain: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Spain: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Russia: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Russia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Others: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Latin America: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Latin America: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Brazil: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Brazil: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Mexico: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Mexico: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Middle East and Africa: Oncolytic Virus Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Middle East and Africa: Oncolytic Virus Therapies Market: Breakup by Country (in %), 2025
  • Figure 70: Middle East and Africa: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Global: Oncolytic Virus Therapies Industry: SWOT Analysis
  • Figure 72: Global: Oncolytic Virus Therapies Industry: Value Chain Analysis
  • Figure 73: Global: Oncolytic Virus Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oncolytic Virus Therapies Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Virus Type (in Million USD), 2026-2034
  • Table 3: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Oncolytic Virus Therapies Market Forecast: Breakup by End Use (in Million USD), 2026-2034
  • Table 5: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Oncolytic Virus Therapies Market: Competitive Structure
  • Table 7: Global: Oncolytic Virus Therapies Market: Key Players